China IIT deaths prompt lawmakers to request FDA clampdown

After several deaths linked to investigational investigational investigational therapies (IITs) in China, lawmakers have called for a crackdown by the Chinese FDA to tighten regulation and oversight of these trials to improve patient safety.

This Wire brief sits within Fusion42's coverage of Biotech.